Revolution Medicines has introduced a new cancer drug, Rasonque (daxorenasib), that carries a list price of approximately $480,000 per year, underscoring ongoing concerns over the cost of oncology treatments in the United States. The oral medication, administered as two pills daily, targets advanced pancreatic cancer—a disease with few effective therapies and limited survival prospects.
In clinical trials, Rasonque demonstrated a median overall survival of 13.2 months for patients with advanced pancreatic cancer, compared with 6.7 months for those receiving standard chemotherapy. While not a cure, the drug’s ability to extend life expectancy has garnered attention within the medical community and among patient advocates.
Brian Crawford, a spokesman for Revolution Medicines, said the drug’s pricing reflects its significant clinical benefits. He added that uninsured or underinsured patients meeting certain financial and medical requirements would be eligible for free access through the company’s patient assistance programs. Prior to FDA approval, the company provided early access to Rasonque at no cost to more than 2,000 patients.
Most of the cost of Rasonque is expected to be covered by insurance plans, with patient out-of-pocket expenses varying based on coverage and deductibles. Experts note that commercially insured patients with high deductibles could face substantial upfront costs, particularly at the start of a new coverage year. However, Medicare beneficiaries stand to benefit from the Inflation Reduction Act’s out-of-pocket cap on prescription drug costs, which currently limits annual spending on covered medications to $2,100 and is set to rise to $4,200 next year. Since pancreatic cancer primarily affects older adults, many patients are expected to be covered under Medicare, which also mandates coverage of cancer drugs as a protected class.
Pharmacy benefit managers, including major companies such as CVS Health’s Caremark and UnitedHealth Group’s Optum Rx, have initiated reviews of Rasonque to determine its coverage parameters. While analysts anticipate the drug will be broadly covered given its demonstrated benefits and the lack of alternative therapies, plans may impose access restrictions—limiting coverage to patients matching the criteria used in clinical trials, such as those who have failed or cannot tolerate chemotherapy. These restrictions could prompt prior authorization requirements, potentially delaying patient access.
The high pricing of Rasonque highlights ongoing challenges in the U.S. pharmaceutical market, where manufacturers set initial list prices largely without regulation or rationale beyond market considerations. Although price negotiations between insurers and drugmakers often reduce costs, cancer therapies tend to see only modest discounts compared with their sticker prices. This trend occurs alongside the rising use of combination treatments in oncology, which can cumulatively drive up expenses for patients and payers.
Revolution Medicines, based near San Francisco, has invested heavily in research and development since its founding in 2014, reporting approximately $3.3 billion in R&D expenses this decade. The company has not yet turned a profit and has registered $4 billion in cumulative losses but has achieved a market capitalization of around $45 billion amid investor optimism about Rasonque’s commercial potential.
Despite the high cost, the drug’s approval and availability represent a meaningful advance in the treatment options for pancreatic cancer patients, many of whom previously faced limited choices and poor prognoses. Healthcare experts emphasize the importance of balancing innovation and affordability to ensure broad patient access to life-extending therapies.